Table II.
Characteristics of the enrolled patients.
| Patient no. | Gender | Age (years) | PS | Disease type | Stage | Previous treatment (months)a | No. of vaccinations | Clinical response | OS (days) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 59 | 0 | ICC | R | GEM + S-1 (2) | 18 | SD | 463 |
| 2 | F | 71 | 1 | GBC | IVb | - | 2 | NA | 57 |
| 3 | F | 59 | 1 | GBC | IVb | GEM→GEM + CDDP (8) | 4 | NA | 35 |
| 4 | M | 57 | 0 | ECC | IVb | GEM + S-1 (3) | 7 | NA | 116 |
| 5 | M | 75 | 0 | GBC | IVb | GEM→GEM + S-1 (2) | 5 | NA | 122 |
| 6 | M | 55 | 0 | PAC | R | S-1→GEM (12) | 14 | SD | 234 |
| 7 | M | 65 | 0 | ECC | R | GEM→GEM + S-1 (4) | 6 | NA | 102 |
| 8 | M | 73 | 1 | ECC | R | GEM→S-1 (27) | 3 | NA | 51 |
| 9 | F | 37 | 1 | ECC | IVb | GEM + UFT→S-1 (7) | 3 | NA | 48 |
| 10 | F | 69 | 0 | ECC | R | GEM→S-1 (12) | 24b | SD | 455c |
| 11 | M | 62 | 0 | ECC | IVa | GEM→S-1 (6) | 8 | NA | 177 |
| 12 | M | 49 | 0 | GBC | R | GEM (6) | 7 | NA | 111 |
| 13 | F | 56 | 0 | ICC | R | - | 16 | SD | 222 |
| 14 | M | 62 | 0 | ECC | R | GEM + S-1(5) | 12 | PD | 286 |
| 15 | M | 53 | 0 | ICC | IVb | GEM (3) | 6 | SD | 84 |
| 16 | M | 75 | 0 | GBC | R | S-1 (2) | 6 | NA | 292 |
| 17 | M | 79 | 0 | ECC | IVb | S-1 (2) | 12 | NA | 355c |
| 18 | M | 59 | 0 | ECC | IVb | GEM (2) | 13 | NA | 207 |
| 19 | F | 56 | 0 | GBC | IVb | GEM (2) | 7 | NA | 92 |
| 20 | M | 71 | 0 | ECC | R | GEM + S-1 (12) | 11 | NA | 163c |
| 21 | M | 51 | 0 | ICC | R | GEM + S-1 (2) | 12 | SD | 179c |
| 22 | M | 66 | 0 | ECC | IVa | GEM (3) | 17b | SD | 179c |
| 23 | M | 52 | 1 | ICC | IVa | 5FU + CDDP→GEM + S-1 (14) | 10 | NA | 101 |
| 24 | M | 41 | 0 | ICC | IVa | GEM (4) | 19b | PD | 428c |
| 25 | F | 48 | 0 | GBC | IVa | - | 14b | SD | 125c |
a
Duration of previous chemotherapy;
b
under treatment;
c
patients alive. M, male; F, female; PS, performance status; ICC, intrahepatic cholangiocarcionma; ECC, extrahepatic cholangiocarcinoma; GBC, gallbladder carcinoma; PAC, periampullary carcinoma; R, recurrent; GEM, gemcitabine; CDDP, cisplatin; UFT, tegafur-uracil; SD, stable disease; PD, progressive disease; OS, overall survival; NA, not assessed.